DOCS — what changed in the latest 10-Q
A section-by-section comparison of DOCS's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-06 vs the prior 10-Q · 2026-02-05
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +28 | −43 | ~22 | 20 |
| Market risk (Item 3) | Text added/removed | +2 | −1 | ~2 | 1 |
| Controls & procedures | Text added/removed | +1 | −1 | ~2 | 0 |
| Legal proceedings | Text added/removed | +1 | −4 | 0 | 0 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +4 | −2 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-06
We are the leading digital platform for U.S. medical professionals, with over 3 million registered members1 as of March 31, 2026. Our registered members represent more than 85% of U.S. physicians, spanning all 50 states and every medical specialty. As of March 31, 2026, the total number of U.S. phys…
1 A registered member is a user who has completed the registration flow on Doximity by either claiming a pre-populated profile or creating a new profile.
Number of customers with at least $500,000 of TTM revenue 127 119
Net Revenue Retention Rate. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Net revenue retention rate is calculated by taking the TTM subscription-based reve…
Quarterly Unique Active Providers using our Workflow Tools. Quarterly unique active providers2 using our Workflow Tools is a measure of our platform’s usage and adoption among healthcare providers on our platform. We calculate the number of unique active providers by counting providers who securely …
Text removed vs the prior filing · source: 10-Q · 2026-02-05
We are the leading digital platform for U.S. medical professionals, as measured by the number of members. Our members include more than 85% of U.S. physicians, spanning all 50 states and every medical specialty.
Net Revenue Retention Rate. Net revenue retention rate is calculated by taking the TTM subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subs…
We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, impairment charge, legal fees associated with certain non-ordinary course legal matters includi…
Three Months Ended December 31,Nine Months Ended December 31,
Change in fair value of contingent earn-out consideration liability79 90 338 513
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-08-06
rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates.
A hypothetical 100 basis point increase in interest rates would have resulted in a decrease of $2.6 million and $3.4 million, respectively, in the market value of our cash equivalents and marketable securities as of June 30, 2026 and March 31, 2026. This estimate is based on a sensitivity model that…
Text removed vs the prior filing · source: 10-Q · 2026-02-05
A hypothetical 100 basis point increase in interest rates would have resulted in a decrease of $4.6 million and $5.4 million, respectively, in the market value of our cash equivalents and marketable securities as of December 31, 2025 and March 31, 2025. This estimate is based on a sensitivity model …
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-06
During the quarter ended June 30, 2026, the Company experienced a transition in its principal financial officer roles. As previously disclosed, our former Chief Financial Officer departed in April 2026, and our Chief Accounting Officer, Siddharth Sitaram, served as interim principal financial office…
Text removed vs the prior filing · source: 10-Q · 2026-02-05
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reason…
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-06
For a description of material legal proceedings in which we are involved, please refer to Note 12—Commitments and Contingencies included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.
Text removed vs the prior filing · source: 10-Q · 2026-02-05
Beginning in April 2024, the Company and certain of our directors and officers have been named in lawsuits in the United States District Court for the Northern District of California. The first lawsuit (the “securities lawsuit”) is captioned In re Doximity, Inc. Securities Litigation, No. 5:24-cv-02…
On December 24, 2025 the parties entered into a settlement, subject to court approval, to resolve the securities lawsuit. Under the terms of the settlement, in exchange for the release and dismissal with prejudice of all claims against the defendants, the Company has agreed to pay and/or to cause it…
On June 20, 2025, the Company, its Chief Technology Officer and its Director of AI Products were named as defendants in a lawsuit in the U.S. District Court for the District of Massachusetts, captioned OpenEvidence Inc. v. Doximity, Inc. et al., No. 1:25-cv-11802-RGS (D. Mass.). On September 17, 202…
For further discussion of our legal proceedings, please refer to Note 13—Commitments and Contingencies included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-06
During the quarter ended June 30, 2026, the Company’s directors and officers adopted or terminated prearranged trading plans intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act as follows:
•On April 27, 2026, Ms. Anna Bryson, former Chief Financial Officer of the Company, terminated a Rule 10b5-1 trading plan that she had previously entered into on May 27, 2025. The plan, which was scheduled to expire pursuant to its terms on May 27, 2026, provided for the sale of up to 160,000 shares…
•On May 22, 2026, Ms. Phoebe Yang, a director of the Company, adopted a Rule 10b5-1 trading plan with a term expiring on October 14, 2026, providing for the sale of up to 1,290 shares of common stock.
•On May 26, 2026, Ms. Kira Wampler, a director of the Company, adopted a Rule 10b5-1 trading plan with a term expiring on May 26, 2028, providing for the sale of up to 54,000 shares of stock issuable upon the exercise of vested stock options.
Text removed vs the prior filing · source: 10-Q · 2026-02-05
On November 26, 2025, Ms. Phoebe Yang, a director of the Company, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Ms. Yang’s Rule 10b5-1 Trading Plan, which has a term from November 26, 2025 to November 26, …
Other than Ms. Yang’s Rule 10b5-1 Trading Plan noted above, during the quarter ended December 31, 2025, none of our directors or executive officers as defined in Rule 16a-1(f) of the Exchange Act adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangeme…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice